[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334285-105":59,"doc-detail-334285-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","antibodydrug-conjugates-as-targeted-therapy-for-treating-gynecologic-cancers-update-2025","Antibody–drug conjugates as targeted therapy for treating gynecologic cancers: update 2025","","This review provides the most up-to-date overview of antibody–drug conjugates (ADCs) in gynecologic cancers, summarizing new research supporting currently approved ADCs and describing ongoing trials that may enable future approvals. It highlights rapid changes in clinical practice, including three FDA-approved ADCs and multiple investigational targets such as folate receptor alpha, Trop-2, CLDN6, CDH6, nectin-4, HER-2, and B7-H4. The review also addresses knowledge gaps, biomarker challenges, and unique toxicities including ocular effects and interstitial lung disease.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/antibodydrug-conjugates-as-targeted-therapy-for-treating-gynecologic-cancers-update-2025/334285/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/antibodydrug-conjugates-as-targeted-therapy-for-treating-gynecologic-cancers-update-2025/334285.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of this review on ADCs in gynecologic cancers?","Question",{"text":112,"@type":113},"To provide the most up-to-date information on antibody–drug conjugates (ADCs) and summarize research supporting approved ADCs, ongoing trials, and preliminary results that may lead to future approvals.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which ADC targets are emphasized for gynecologic cancers?",{"text":117,"@type":113},"Folate receptor alpha is the most common target, with eight folate receptor targeting ADCs in development. Other investigated targets include Trop-2, CLDN6, CDH6, nectin-4, HER-2, and B7-H4.",{"name":119,"@type":110,"acceptedAnswer":120},"What unique adverse effects can ADCs cause?",{"text":121,"@type":113},"ADCs can lead to new and unique toxicities, including ocular toxicities and interstitial lung disease, which require preventive measures and close monitoring.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334285,1790198639,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","REVIEW  \nUPRI RNIENTON Antibody–drug conjugates as targeted therapy for  \ntreating gynecologic cancers: update 2025  \nJordyn Silverstein a, Beth Karlan b, Nasim Herringtona and Gottfried Konecnya  \nPurpose of review  \nProvide the most up-to-date information on the dynamic landscape of antibody–drug conjugates (ADCs) in gynecologic cancers. We discuss the latest research that supports the approved ADCs and outline the ongoing trials and preliminary results that may lead to ADC approvals in the future. Current gaps in knowledge and areas for future research are discussed.  \nRecent findings  \nADCs are rapidly changing the landscape of gynecologic cancer care. Three ADCs are currently FDA approved and used routinely in clinical practice, with many more currently in clinical development. The most common ADC target is folate receptor alpha of which there are 8 different folate receptor targeting ADCs in development. Other targets under investigation include trophoblast cell surface antigen-2 (Trop-2), claudin-6 (CLDN6), cadherin-6 (CDH6), nectin-4, HER-2 and B7-H4 . ADCs can cause new and unique adverse effects, including ocular toxicities and interstitial lung disease.  \nSummary  \nADCs offer the opportunity for a more effective and personalized treatment approach for gynecologic cancer patients. Side effects must be closely monitored, and preventive measures must be followed to maximize benefit and minimize toxicity. A better understanding of the role of target proteins as biomarkers to predict response to ADCs will be critical for successful clinical implementation of ADCs and further research in this area is necessary.  \nKeywords  \nantibody–drug conjugates, gynecologic cancer  \nINTRODUCTION  \nAntibody drug conjugates (ADCs) combine the capabilities of targeted monoclonal antibodies with traditional cytotoxic agents. ADCs have three main components: a highly selective monoclonal antibody for a tumor-associated surface antigen, a potent cytotoxic agent to induce cell death after cellular internalization of the payload, and a linker that is stable while in circulation but releases the cytotoxic agent when in the target cells [1&] .  \nADC approvals over the last year for gynecologic cancers include mirvetuximab soravtansine-gynx (MIRV) for the treatment of platinum resistant ovarian cancer (PROC) in March 2024 [2] . This was followed by the pan-cancer approval of trastuzumab-dertuxtecan (T-DXd) in April for any solid tumor that is HER2-positive, including endometrial (EC), cervical (CC), and ovarian cancer (OC) [3] . Tisotumab vedotin (TV) was also approved in April for recurrent or metastatic CC (r/mCC) following progression after chemotherapy [4] .  \nIn this review, we discuss the studies that support the approval of the currently approved ADCs  \nand outline the ongoing trials that may lead to ADC approvals in the near future. Additionally, innovation leads to many more questions than answers, and we will discuss the current gaps in knowledge and areas for future research.  \naDivision of Hematology/Oncology, Department of Medicine, University of California, Los Angeles (UCLA) and bDepartment of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA  \nCorrespondence to Jordyn Silverstein, MD, Division of Hematology and Oncology, University of California, Los Angeles 757 Westwood Plaza, Los Angeles, CA 90095, USA. Tel: +1 310 825 9111;  \ne-mail: [JSilverstein@mednet.ucla.edu](JSilverstein@mednet.ucla.edu)  \n[Curr Opin Obstet Gynecol](Curr Opin Obstet Gynecol 2025)[ 2025](Curr Opin Obstet Gynecol 2025), [37:5](37:5)–15  \nDOI:10.1097/GCO.0000000000001002  \nThis is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in anyway or used commercially without permission from the journal.  \n1040-872X ","cbCaipu3kxEpDw2E","https://ap.wps.com/l/cbCaipu3kxEpDw2E","pdf",746341,11,"English","# Purpose of review\n# Recent findings\n# Summary\n# Introduction\n# ADC approvals over the last year for gynecologic cancers\n# Overview of antibody–drug conjugates","[{\"question\":\"What is the purpose of this review on ADCs in gynecologic cancers?\",\"answer\":\"To provide the most up-to-date information on antibody–drug conjugates (ADCs) and summarize research supporting approved ADCs, ongoing trials, and preliminary results that may lead to future approvals.\"},{\"question\":\"Which ADC targets are emphasized for gynecologic cancers?\",\"answer\":\"Folate receptor alpha is the most common target, with eight folate receptor targeting ADCs in development. Other investigated targets include Trop-2, CLDN6, CDH6, nectin-4, HER-2, and B7-H4.\"},{\"question\":\"What unique adverse effects can ADCs cause?\",\"answer\":\"ADCs can lead to new and unique toxicities, including ocular toxicities and interstitial lung disease, which require preventive measures and close monitoring.\"}]","Antibody–drug conjugates as targeted therapy for treating gynecologic cancers: update 2025 | PDF",1790006130,28]